CareDx, Inc (FRA:1K9)
| Market Cap | 792.63M |
| Revenue (ttm) | 305.12M |
| Net Income (ttm) | 60.05M |
| Shares Out | n/a |
| EPS (ttm) | 1.04 |
| PE Ratio | 13.20 |
| Forward PE | 17.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 0 |
| Open | 15.11 |
| Previous Close | 15.24 |
| Day's Range | 15.11 - 15.11 |
| 52-Week Range | 9.83 - 24.43 |
| Beta | n/a |
| RSI | 60.84 |
| Earnings Date | Feb 27, 2026 |
About CareDx
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to typ... [Read more]
News
SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiat...
SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation
CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transp...
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization ...
CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization ...
CDNA: BTIG Raises Price Target to $25, Maintains Buy Rating | CDNA Stock News
CDNA: BTIG Raises Price Target to $25, Maintains Buy Rating | CDNA Stock News
After-Hours Gainers: VCYT, RIGL, NPCE, CDNA, And FBLG Post Notable Moves Following Q3 Results
(RTTNews) - Several healthcare and biotech names posted strong after-hours gains on Tuesday following the release of third-quarter earnings and updated guidance for the remainder of 2025. The session ...
CareDx Inc (CDNA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance
CareDx Inc (CDNA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance
CareDx raises 2025 revenue guidance to $372M–$376M with robust RCM gains and new product launches
CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript
CareDx, Inc (CDNA) Q3 2025 Earnings Call November 4, 2025 4:30 PM ESTCompany ParticipantsTina JacobsenJohn Hanna - President, CEO & DirectorNathan Smith...
Q3 2025 CareDx Inc Earnings Call Transcript
Q3 2025 CareDx Inc Earnings Call Transcript
CareDx (CDNA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for CareDx (CDNA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar...
CareDx Inc (CDNA) Q3 2025 Earnings: EPS of $0. ...
CareDx Inc (CDNA) Q3 2025 Earnings: EPS of $0.03 Beats Estimate, Revenue Surpasses Expectations at $100.1 Million
CareDx Announces Third Quarter 2025 Financial Results
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthc...
CareDx Announces Third Quarter 2025 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically...
CareDx Q3 2025 Earnings Preview
CareDx Inc (CDNA) Q3 2025 Earnings Report Preview: What To Expect
CareDx Inc (CDNA) Q3 2025 Earnings Report Preview: What To Expect
CareDx Appoints Jeffrey Teuteberg As CMO
(RTTNews) - CareDx, Inc. (CDNA), a precision medicine company, said on Monday that it has appointed Jeffrey John Teuteberg as its Chief Medical Officer with effect from October 1.
CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer
CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healt...
CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinica...
CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiat...
CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiate...
CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization ...
CareDx Issues Comment Letter on Draft LCD Policy
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...